ABBV 744
Alternative Names: ABBV-744Latest Information Update: 29 Nov 2023
At a glance
- Originator AbbVie
- Class Antineoplastics; Small molecules
- Mechanism of Action BRD2 protein inhibitors; BRD3 protein inhibitors; BRD4 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Acute myeloid leukaemia; Myelofibrosis; Prostate cancer
Most Recent Events
- 29 Nov 2023 Discontinued - Phase-I for Acute myeloid leukaemia (Metastatic disease, Second-line therapy or greater) in USA (PO) (AbbVie pipeline, November 2023)
- 29 Nov 2023 Discontinued - Phase-I for Myelofibrosis (Adjunctive treatment, Combination therapy, Treatment-experienced) in Israel (PO) (AbbVie pipeline, November 2023)
- 29 Nov 2023 Discontinued - Phase-I for Myelofibrosis (Adjunctive treatment, Combination therapy, Treatment-experienced) in USA (PO) (AbbVie pipeline, November 2023)